Genmab-CEO: Drug could be ready in 2016
The special status given to a candidate drug from Genmab could cut years off the development. The company’s CEO has talked to Medwatch about the future of the company following a number of promising announcements.
by Leonora Beck
Big-spending investors have been ripping Genmab shares of the shelves in the beginning of the year and last week the share went up by another 12 % in one day, following to positive announcements from the company:
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Major boost for Genmab’s candidate drug
For abonnenter
